

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N. 139 281 173

**Financial Report
For the year ended 30 June 2012**

Contents

Directors' report	1
Auditor's Independence Declaration	9
Statement of Comprehensive Income	10
Statement of Financial Position	11
Statement of Changes in Equity	12
Statement of Cash Flows	12
Notes to the Financial Statements	13
Directors' Declaration	28
Independent Audit Report	29
Compilation Report on Additional Financial Data	30
Statement of Comprehensive Income	31

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

DIRECTORS' REPORT

Your directors present this report on the company for the financial year ended 30 June 2012.

Directors

The names of each person who has been a director during the period and to the date of this report are:

Dr Edwina Wright	Dr William Donohue
Dr Mark Bloch	Professor Greg Dore
Dr Mark Boyd	Dr Jullian Elliott (appointed 28.09.11)
Professor Graham Cooksley (resigned 22.06.12)	Dr Michelle Giles (resigned 28.09.11)
Professor David Cooper (appointed 28.09.11)	Dr Louise Owen
Dr Benjamin Cowie	Professor Patricia Price
Mr Philip Cunningham	Dr Darren Russell
Ms Lyndal Daly	Mr Mark Saunders (appointed 21.05.12)

Directors have been in office since the start of the financial period to the date of this report unless otherwise stated.

The following person who held the position of company secretary at the end of the financial period was:

Ms Levinia Crooks, AM

Company Secretary

The following person held the position of entity secretary at the end of the financial period:

Ms Levinia Crooks has worked for the Australasian Society for HIV Medicine Inc since 1999 as Chief Executive Officer and has worked for the Australasian Society for HIV Medicine, (ASHM) a Company Limited by Guarantee, since 4 September, 2009, performing the role of Chief Executive Officer. Ms Levinia Crooks was appointed as Company Secretary when ASHM became a Company Limited by Guarantee on 4 September 2009.

Operating Results

Excess of revenue over expenditure amounted to \$79,342 (2011: \$27,381)

Principal Activities

The principal activities of the entity during the financial period were to act as the peak representative professional body for medical practitioners and other health care professionals in Australia and New Zealand who work in HIV, viral hepatitis and related diseases.

Short-term and Long-term Objectives

The ASHM's short-term objectives are to:

Reduce the impact of HIV, viral hepatitis and sexually transmissible infections through:

- the facilitation of workforce development activities and supporting the health workforce
- the promotion of informed public debate
- supporting the delivery of quality health care, domestically and regionally, and
- responding to the needs of our members and the sector

The ASHM's long-term objectives are to:

Reduce the impact of HIV, viral hepatitis and sexually transmissible infections through:

- supporting research and programmatic endeavors which may lead to the eradication of these conditions
- sustaining and supporting collaborations across and between disciplines and internationally, regionally and domestically which will facilitate these long and short term objectives.

Strategies

To achieve its stated objectives, the company has adopted the following strategies:

- We seek funding and use funding from Government and non-government sources in support of our activities
- We work collaboratively with individuals and organisations to support and contribute to the sector through the provision of workforce development, the generation of resources and the development and maintenance of standards

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

DIRECTORS' REPORT (CONTINUED)

Key Performance Measures

The company measures its own performance through the use of both quantitative and qualitative indicators. These data are used by the directors to assess the financial sustainability of the company and whether the company's short-term and long-term objectives are being achieved.

Members	2012	2011
Number of members	1,181	1,145
Collaborators		
Number of domestic partner organisations	19	10
Number of affiliates	375	241
Number of regional partner organisations	7	7
Staff		
Number of staff employed for 5 years or more	10	9
Training and Resources		
Number of courses run	79	75
Number of resources distributed	43,978	53,438
Number of pdf resources downloaded	26,074	16,344
Operational and Financial		
Total Revenue	\$11,016,715	\$10,403,583
Proportion of funding provided by:		
government grants	34%	37%
Non-government grants	6%	4%
Donations received from public	0.74%	0.25%
Proportion of funding spent on:		
Staff training	0.26%	0.36%
General office/administration	3%	3%
fundraising	0.12%	0.03%

Dividends Paid or Recommended

The entity is a not for profit company limited by guarantee. In accordance with the company's Constitution no dividend is payable.

Events Subsequent to Balance Date

There have been no significant events after 30 June 2012 to date of signing report.

Future Developments

The entity expects to maintain the present status and level of operations.

Environmental Issues

The company's operations are not regulated by any significant environmental regulation under a law of the Commonwealth or of a state or territory.

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

DIRECTORS' REPORT (CONTINUED)

Member Numbers

The number of members registered in the Register of Members as at 30 June 2012 was 1,181 (2011: 1,145). It should be noted that ASHM has expanded its reach within the sector through its organisational program. This allows an organisation to give its staff the benefits of membership, without requiring them to take out individual membership. This has resulted in a very minor increase in individual voting membership and increased the number of people getting the benefits of membership, see collaborators above.

The entity is incorporated under the *Corporations Act 2001* and is an entity limited by guarantee. If the entity is wound up, the constitution states that each member is required to contribute a maximum of \$1 each towards meeting any outstanding obligations of the entity. At 30 June 2012, the total amount that members of the company are liable to contribute if the company is wound up is \$1,181 (2011: 1,145).

Information on Directors in Office at the Date of this Report

- | | |
|------------------|---|
| Dr Edwina Wright | — President |
| | — MB BS FRACP PhD |
| | — Dr Edwina Wright, from the Alfred Hospital in Melbourne, is an infectious diseases physician with a particular interest in neurological issues. Recently Edwina has been involved in establishing the Asia-Pacific NeuroAIDS Consortium, the Australian National NeuroAIDS Brain and Tissue Bank and in developing clinical research protocols in the area of HIV neurology. |
| | — As President, Edwina chairs the Risk Management and Audit Sub-Committee of the ASHM Board. |
| Dr Mark Bloch | — Board Member |
| | — MBBS M Med |
| | — Dr Mark Bloch has been working in the field of HIV medicine since 1983; he was a doctor at Sydney Hospital and Albion St AIDS clinic prior to being a director at Holdsworth House. He has completed his Masters in Medicine, HIV and Sexual Health from University of Sydney, and he is a past President of the Sexual Health Society of NSW. Mark is the director of clinical trials at Holdsworth House and actively involved in clinical research in HIV and STIs, co-joint lecturer at University of NSW, and a member of medical advisory boards. |
| Dr Mark Boyd | — Vice President |
| | — BA BM BS MHID MD FRACP |
| | — Dr Mark Boyd is an Infectious Diseases and HIV physician working primarily in clinical research at the Kirby Institute at UNSW. He is also a Consultant Physician at St. Vincent's Hospital, Sydney, Australia. |
| | — As a Vice-President, Mark sits on the Risk Management and Audit Sub-Committee of the ASHM Board. |

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

DIRECTORS' REPORT (CONTINUED)

- Professor Graham Cooksley— Board Member till 22.06.12
- MBBS FRACP MD
 - Prof Graham Cooksley works in the Discipline of Medicine, Univ of Qld, at Royal Brisbane Hospital, Brisbane QLD. Since writing a review on the Australia Antigen in 1972 Graham Cooksley has had an interest in Hepatitis B, and then Hepatitis C from a research, clinical, anthropological and public health view. He has been co-convenor of several international meetings on Hepatitis C and Hepatitis D. Recently he has been on Data Management Committees of clinical trials, involving Primary Health Carers in Hepatitis B, on the APASL guidelines committee for Hepatitis B.
 - Graham occupied an invited position as the 10th Ordinary Director on the ASHM Board.
- Prof David Cooper
- Board Member
 - BSc(Med) MBBS (Syd), MD, DSc(UNSW), FRCPA, FRCP, FAA
 - David Cooper AO, Scientia Professor of Medicine at the University of New South Wales and a Fellow of the Australian Academy of Science (FAA), is Director of the St Vincent's Centre for Applied Medical Research (AMR) and the Kirby Institute, which conducts research into HIV/AIDS with the ultimate aim of reducing the burden of the epidemic for the affected community. He is a Director of HIV-NAT, a clinical research and trial collaboration in Thailand and is a past President of the International AIDS Society (IAS) and Chairman of the WHO-UNAIDS HIV Vaccine Advisory Committee (VAC).
- Dr Benjamin Cowie
- Board Member
 - MBBS PhD GradDipClinEpi FRACP
 - Dr Benjamin Cowie is an infectious diseases physician with the Victorian Infectious Diseases Service at the Royal Melbourne Hospital. He has a particular clinical interest in viral hepatitis.
- Mr Philip Cunningham
- Vice President
 - BSc(Med)Hons QSA
 - Mr Philip Cunningham is the Senior Scientist and Operations Manager of the NSW State Reference Laboratory for HIV/AIDS at St Vincent's Hospital, Sydney. Philip is a visiting research fellow at the National Centre in HIV Epidemiology and Clinical Research at the University of New South Wales and is Chief of Operations for the St Vincent's broader research campus.
 - Philip sits on the Risk Management and Audit Sub-Committee of the ASHM Board and Co-chair of the HIV Testing Policy Expert Advisory Group.

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

DIRECTORS' REPORT (CONTINUED)

Ms Lyndal Daly	<ul style="list-style-type: none">— Board Member— RGN BN Grad Dip Crit Care— Lyndal Daly is a Clinical Practice Consultant in the Infectious Diseases Unit at the Royal Adelaide Hospital. This involves all aspects of Infectious Diseases including inpatient care and managing and coordinating the outpatient clinic. For 6 years she has also been undertaking the HIV clinical trials and research. Lyndal was an Intensive Care Nurse for 11 years prior to joining the Infectious Diseases world.
Dr William Donohue	<ul style="list-style-type: none">— Board Member— MBBS., B.Med.Sc— Dr William Donohue is a general practitioner with an active interest in HIV and viral hepatitis. He is the primary care representative on the SA Health Steering Committee for HIV and HCV, a member of the GP Credentialing Committee and Level 2 GP educator.
Professor Gregory Dore	<ul style="list-style-type: none">— Immediate Past President— BSc MBBS FRACP MPH PhD— Prof Greg Dore is Professor and Head, Viral Hepatitis Clinical Research Program, Kirby Institute, The University of New South Wales, Sydney. Infectious Diseases Physician, St Vincent's Hospital, Sydney. Greg has been involved in the areas of HIV and viral hepatitis for 15 years, in academic research, clinical, and public health policy capacities.— As Immediate Past President, Greg sits on the Risk Management and Audit Subcommittee of the ASHM Board.
Dr Jullian Elliott	<ul style="list-style-type: none">— Board Member— MBBS FRACP— Dr Julian Elliot is Head of Clinical Research at the Alfred Hospital Infectious Diseases Unit, Senior Lecturer at Monash University and HIV Clinical Advisor at the Burnett Institute. His research interests are the use of ARV in low and middle income countries, including treatment monitoring and failure and immune restoration. He is a leader of the NHMRC funded HealthMap project looking at patient self management in HIV. He was a technical advisor to the Cambodian Ministry of Health and contributed to the rapid expansion of treatment in Cambodia. He is also a WHO, UNAIDS and World Bank reviewer of HIV programs and guidelines.
Dr Michelle Giles	<ul style="list-style-type: none">— Board Member till 28.09.11— MBBS FRACP PhD— Dr Michelle Giles is an infectious diseases physician with clinical appointments at the Alfred Hospital, the Royal Women's Hospital and Monash Medical Centre in Melbourne. Dr Giles works on the HIV discordant couple programme at the Royal Women's Hospital assisting couples with reproduction where one partner has HIV infection.

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

DIRECTORS' REPORT (CONTINUED)

- | | |
|--------------------------|--|
| Dr Louise Owen | <ul style="list-style-type: none">— Board Member
— MBBS (Hons) FRACP FACHSHM
Louise is a Sexual Health Physician in Hobart, Tasmania, working in youth sexual health services and Hepatitis C services at the Royal Hobart Hospital. She holds a clinical teaching appointment at the University of Tasmania Medical School and lectures in sexual health at undergraduate and postgraduate levels. Louise has been the Clinical Director of the Gay Men's Health Centre for the Victorian AIDS Council and still consults to them. She is also a member of the HCV Testing Policy Expert Reference Committee. |
| Professor Patricia Price | <ul style="list-style-type: none">— Board Member
— MSc PhD
— Prof Patricia Price began as a laboratory-based immunologist with an interest in problems facing the majority world - malnutrition, parasite infections and finally viruses. After almost 20 years in Dept of Microbiology (U WA) working with laboratory mice, Patricia moved to Dept of Clinical Immunology & Immunogenetics (RPH) in 1996. She now supervises graduate students in Western Australia, Indonesia and South Africa. Projects centre on immunological responses of HIV patients to ART, with a focus on immune restoration disease, toxic neuropathy and co-infections with HCV or CMV
— Patricia is a member of the ASHM Conference Advisory Committee. |
| Dr Darren Russell | <ul style="list-style-type: none">— Board Member
— MB BS FRACGP DipVen FACHSHM
— Dr Darren Russell is the Director of Sexual Health at Cairns Base Hospital and holds the positions of Clinical Associate Professor in the Department of Population Health at The University of Melbourne and Adjunct Associate Professor in the Faculty of Medicine, Health and Molecular Science at James Cook University. Darren is a Past President of the Australasian Chapter of Sexual Health Medicine, and is a past President of the Australian Federation of AIDS Organisations.
— Darren is a member of the Expert Reference Group for the ASHM Aboriginal & Torres Strait Islander Program. |
| Mr Mark Saunders | <ul style="list-style-type: none">— Board Member
— Mark is the Sexual Health, Blood Borne Viruses, Male Health and Research Policy Officer with the National Aboriginal Community Controlled Health Organisation NACCHO. Mark has worked in the HIV sector for 20 years and held a number of education, policy and research positions.
Mark is a member of the Expert Reference Group for the AHM Aboriginal & Torres Strait Islander Program
Mark occupies the 11th Ordinary Director position on the Board, a designated Aboriginal and Torres Strait Islander position which is appointed by the Board. |

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

DIRECTORS' REPORT (CONTINUED)

ATTENDANCE AT DIRECTORS MEETINGS

Name	Board Meetings	Meetings of Risk Management and Audit Sub-Committee
Mark Bloch	6 (9)	
Mark Boyd	6 (9)	3 (4)
Graham Cooksley	5 (9)	
David Cooper	2(6)	
Benjamin Cowie	8 (9)	
Philip Cunningham	8(9)	2 (4))
Lyndal Daly	9 (9)	
William Donohue	8 (9)	
Gregory Dore	3 (9)	2 (4)
Michelle Giles	1 (3)	
Jullian Elliott	6(6)	
Louise Owen	8 (9)	
Patricia Price	7 (9)	
Darren Russell	6 (9)	
Mark Saunders	1(1)	
Edwina Wright	7 (9)	4 (4)

Figures in brackets indicate the maximum number of Board Meetings directors were eligible to attend.

Indemnifying Officers or Auditor

No indemnities have been given or insurance premiums paid, during or since the end of the financial year, for any person who is or has been an officer or auditor of the entity.

Proceedings on Behalf of the Entity

No person has applied for leave of Court to bring proceedings on behalf of the entity or intervene in any proceedings to which the entity is a party for the purpose of taking responsibility on behalf of the entity for all or any part of those proceedings.

The entity was not a party to any such proceedings during the period.

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173


A COMPANY LIMITED BY GUARANTEE

DIRECTORS' REPORT (CONTINUED)

Auditor's Independence Declaration

The lead auditor's independence declaration for the period ended 30 June 2012 has been received and can be found on page 9 of the directors' report.

Signed in accordance with a resolution of the Board of Directors:



Prof Gregory Dore BSc MBBS FRACP MPH PhD



Dr Mark Boyd BA BM BS MHID MD FRACP

Dated this 19th day of September 2012

ABN 55 931 152 366

8th Floor,
55 Hunter Street
SYDNEY NSW 2000

GPO Box 4836
SYDNEY NSW 2001

Telephone: +61 2 9951 5400
Facsimile: +61 2 9951 5454
mail@wwnsw.com.au

Website www.wwnsw.com.au

**AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF AUSTRALASIAN SOCIETY FOR HIV MEDICINE**

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2012 there have been:

- (i) no contraventions of the auditors' independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- (ii) no contraventions of any applicable code of professional conduct in relation to the audit.

Walker Wayland n s w A S Roger

Walker Wayland NSW
Chartered Accountants

A S Roger
Partner

Dated this 19th day of September 2012

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2012

		2012 \$	2011 \$
	Note		
REVENUE			
<i>Operating Activities</i>			
Members' subscriptions		83,003	37,360
Operating grants	3	4,339,237	4,190,324
Donations		81,614	26,210
Service fee and other revenue from operating activities		969,855	1,084,675
Sponsorship		124,909	116,591
Conference		5,171,510	4,836,914
<i>Non-operating activities</i>			
Interest		109,739	111,509
Support to the sector		136,849	-
	2	<u>11,016,715</u>	<u>10,403,583</u>
EXPENSES			
General office administration		339,134	317,627
Occupancy costs		260,976	254,149
Education programs / resources		1,692,484	1,935,249
Professional fees		274,490	120,083
Personnel expenses		3,829,952	3,541,703
Loss on disposal on assets		325	1,059
Impairment loss	3	-	12,030
Depreciation	3	85,274	92,541
Finance expenses		10,474	10,357
Conference costs		4,307,416	4,091,404
Support to the sector		136,849	-
TOTAL EXPENSES		<u>10,937,373</u>	<u>10,376,202</u>
EXCESS/(SHORTFALL) OF REVENUE OVER EXPENDITURE BEFORE INCOME TAX EXPENSE	3	79,342	27,381
Income tax expense relating to ordinary activities		-	-
EXCESS/(SHORTFALL) OF REVENUE OVER EXPENDITURE AFTER INCOME TAX EXPENSE		<u>79,342</u>	<u>27,381</u>
OTHER COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX		-	-
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		<u>79,342</u>	<u>27,381</u>

Note: References to **Excess of Revenue over Expenses from Continuing Operations** should be taken to mean **Profit**.

The accompanying notes form part of these financial statements

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2012

		2012 \$	2011 \$
	Note		
CURRENT ASSETS			
Cash and cash equivalents	5	3,317,651	3,229,371
Trade and other receivables	6	1,265,076	852,685
Other financial asset	8	400,000	400,000
Other current assets	7	6,975	19,735
TOTAL CURRENT ASSETS		<u>4,989,702</u>	<u>4,501,791</u>
NON-CURRENT ASSETS			
Other financial asset	8	58,489	58,489
Property, plant and equipment	9	279,242	331,120
TOTAL NON-CURRENT ASSETS		<u>337,731</u>	<u>389,609</u>
TOTAL ASSETS		<u>5,327,433</u>	<u>4,891,400</u>
CURRENT LIABILITIES			
Trade and other payables	10	2,178,530	1,912,050
Provisions	11	301,409	202,298
TOTAL CURRENT LIABILITIES		<u>2,479,939</u>	<u>2,114,348</u>
NON-CURRENT LIABILITIES			
Provisions	12	104,564	113,464
TOTAL NON-CURRENT LIABILITIES		<u>104,564</u>	<u>113,464</u>
TOTAL LIABILITIES		<u>2,584,503</u>	<u>2,227,812</u>
NET ASSETS		<u>2,742,930</u>	<u>2,663,588</u>
EQUITY			
Retained earnings		<u>2,742,930</u>	<u>2,663,588</u>
TOTAL EQUITY		<u>2,742,930</u>	<u>2,663,588</u>

The accompanying notes form part of these financial statements

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2012

	Retained Earnings \$	Total \$
BALANCE AT 30 June 2010	2,636,207	2,636,207
Excess of revenue over expenditure for the period	27,381	27,381
Other comprehensive income for the period	-	-
BALANCE AT 30 June 2011	2,663,588	2,663,588
Excess of revenue over expenditure for the period	79,342	79,342
Other comprehensive income for the period	-	-
BALANCE AT 30 June 2012	2,742,930	2,742,930

Note: References to **Excess of Revenue over Expenses from Continuing Operations** should be taken to mean **Profit**.

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2012

	Note	2012 \$	2011 \$
CASH FLOW FROM OPERATING ACTIVITIES			
Receipts from operation		11,585,283	11,120,038
Payments to suppliers and employees		(11,573,021)	(11,223,762)
Interest received		109,739	111,509
Net cash provided by operating activities	14b	122,001	7,785
CASH FLOW FROM INVESTING ACTIVITIES			
Payments for property, plant and equipment		(33,721)	(48,940)
Loss from disposal of property, plant and equipment		-	-
Payment for held to-maturity investment		-	(400,000)
Net cash used in investing activities		(33,721)	(448,940)
NET INCREASE / (DECREASE) IN CASH HELD		88,280	(441,155)
Cash and cash equivalents at beginning of financial year		3,229,371	3,670,526
CASH AND CASH EQUIVALENTS AT END OF FINANCIAL YEAR	14a	3,317,651	3,229,371

The accompanying notes form part of these financial statements

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

The financial report includes the financial statements and notes of Australasian Society For HIV Medicine as an individual company, incorporated and domiciled in Australia. Australasian Society For HIV Medicine is a company limited by guarantee.

Basis of Preparation

The financial report is a general purpose financial report that has been prepared in accordance with Australian Accounting Standards, Australian Accounting Interpretations, other authoritative pronouncements of the Australian Accounting Standards Board and the *Corporations Act 2001*. The financial report also incorporates elements of the Australian Council for International Development (ACFID) Code of Conduct.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in a financial report containing relevant and reliable information about transactions, events and conditions to which they apply. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards. Material accounting policies adopted in the preparation of this financial report are presented below. They have been consistently applied unless otherwise stated.

The financial report has been prepared on an accruals basis and is based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets, and financial liabilities.

The financial statements were authorised for issue on 19TH September 2012 by the directors of the company.

Accounting Policies

a. Revenue

Revenue from Grants is recognised in accordance within the terms of the grant agreement.

Interest revenue and distribution income from investments is recognised on a proportional basis taking into account the interest rates applicable to the financial assets.

Revenue from the rendering of a service is recognised upon the delivery of the service to the customers.

b. Property, Plant and Equipment

Each class of property, plant and equipment is carried at cost or fair value less, where applicable, accumulated depreciation and impairment losses.

Plant and Equipment

Plant and equipment are measured at cost or fair value less depreciation and impairment losses.

The carrying amount of plant and equipment is reviewed annually to ensure it is not in excess of the recoverable amount from these assets. The recoverable amount is assessed on the basis of the expected net cash flows that will be received from the assets employment and subsequent disposal.

Plant and equipment that have been contributed at no cost or for nominal cost are valued at the fair value of the asset at the date it is acquired.

Depreciation

The depreciable amount of all fixed assets including buildings and capitalised lease assets, but excluding freehold land, is depreciated on a diminishing balance basis over their useful lives to the economic company commencing from the time the asset is held ready for use. Leasehold improvements are depreciated over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements.

The depreciation rates used for each class of depreciable assets are:

Class of Fixed Asset	Depreciation Rate
Office Equipment	20%
Computer Equipment	20-40%
Leasehold Improvement	12.5%
Furniture and Finishing	5-12.5%
Software	30-40%
Motor Vehicles	18.75%

These notes form part of the financial statements

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

b. **Property, Plant and Equipment (continued)**

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

Asset classes carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains or losses are included in the statement of comprehensive income. When revalued assets are sold, amounts included in the revaluation reserve relating to that asset are transferred to retained earnings.

c. **Income in advance**

Income received before the due date is recorded as income in advance under the appropriate category.

d. **Financial Instruments**

Initial recognition and measurement

Financial instruments, incorporating financial assets and financial liabilities, are recognised when the company becomes a party to the contractual provisions of the instrument. Trade date accounting is adopted for financial assets that are delivered within timeframes established by marketplace convention.

Financial instruments are initially measured at fair value plus transaction costs where the instrument is not classified at fair value through profit or loss. Transaction costs related to instruments classified at fair value through profit or loss are expensed to profit or loss immediately. Financial instruments are classified and measured as set out below.

Classification and subsequent measurement

Financial instruments are subsequently measured at fair value, amortised cost using the effective interest rate method or cost. *Fair value* represents the amount for which an asset could be exchanged or a liability settled, between knowledgeable, willing parties. Where available, quoted prices in an active market are used to determine fair value. In other circumstances, valuation techniques are adopted.

Amortised cost is calculated as:

- i. the amount at which the financial asset or financial liability is measured at initial recognition;
- ii. less principal repayments;
- iii. plus or minus the cumulative amortisation of the difference, if any, between the amount initially recognised and the maturity amount calculated using the *effective interest method*; and
- iv. less any reduction for impairment.

The *effective interest method* is used to allocate interest income or interest expense over the relevant period and is equivalent to the rate that exactly discounts estimated future cash payments or receipts (including fees, transaction costs and other premiums or discounts) through the expected life (or when this cannot be reliably predicted, the contractual term) of the financial instrument to the net carrying amount of the financial asset or financial liability. Revisions to expected future net cash flows will necessitate an adjustment to the carrying value with a consequential recognition of an income or expense in profit or loss.

(i) *Held-to-maturity investments*

Held-to-maturity investments are non-derivative financial assets that have fixed maturities and fixed or determinable payments, and it is the company's intention to hold these investments to maturity. They are subsequently measured at amortised cost.

Held-to-maturity investments are included in non-current assets, except for those which are expected to mature within 12 months after the end of the reporting period.

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Financial Instruments (continued)

(ii) *Loans and receivables*

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are subsequently measured at amortised cost.

Loans and receivables are included in current assets, except for those which are not expected to mature within 12 months after the end of the reporting period, which will be classified as non-current assets.

(iii) *Financial liabilities*

Non-derivative financial liabilities (excluding financial guarantees) are subsequently measured at amortised cost.

Fair Value

Fair value is determined based on current bid prices for all quoted investments. Valuation techniques are applied to determine the fair value for all unlisted securities, including recent arm's length transactions, reference to similar instruments and option pricing models.

Impairment

At the end of each reporting period, the company assesses whether there is objective evidence that a financial instrument has been impaired. In the case of available-for-sale financial instruments, a prolonged decline in the value of the instrument is considered to determine whether an impairment has arisen. Impairment losses are recognised in the statement of comprehensive income.

Derecognition

Financial assets are derecognised where the contractual rights to receipt of cash flows expires or the asset is transferred to another party whereby the company no longer has any significant continuing involvement in the risks and benefits associated with the asset. Financial liabilities are derecognised where the related obligations are either discharged, cancelled or expired. The difference between the carrying value of the financial liability, which is extinguished or transferred to another party and the fair value of consideration paid, including the transfer of non-cash assets or liabilities assumed, is recognised in profit or loss.

e. Impairment of Assets

At each reporting date, the company reviews the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, is compared to the asset's carrying value. Any excess of the asset's carrying value over its recoverable amount is expensed to the statement of comprehensive income.

Where the future economic benefits of the asset are not primarily dependent upon on the assets ability to generate net cash inflows and when the company would, if deprived of the asset, replace its remaining future economic benefits, value in use is depreciated replacement cost of an asset.

Where it is not possible to estimate the recoverable amount of an assets class, the company estimates the recoverable amount of the cash-generating unit to which the class of assets belong.

f. Employee Benefits

Provision is made for the company's liability for employee benefits arising from services rendered by employees to the end of the reporting period. Employee benefits expected to be settled within one year together with benefits arising from , salaries and annual leave which may be settled after one year, have been measured at the amounts expected to be paid when the liability is settled plus related on costs. Other employee benefits payable later than one year have been measured at the net present value discounted using market yields on national government bonds with terms to maturity that match the expected timing of cash flows.

Contributions are made by the company to an employee superannuation fund. These are charged as expenses when incurred.

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

g. **Cash and Cash Equivalents**

Cash and cash equivalents include cash on hand, deposits held at-call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within short-term borrowings in current liabilities on the statement of financial position.

h. **Accounts Receivable and Other Debtors**

Accounts receivable and other debtors include amounts due from members as well as amounts receivable from customers for goods and services sold in the ordinary course of business. Receivables expected to be collected within 12 months of the end of the reporting period are classified as current assets. All other receivables are classified as non-current assets.

Accounts receivable are initially recognised at fair value and subsequently measured at amortised cost using the effective interest rate method, less any provision for impairment. Refer to Note 1(e) for further discussion on the determination of impairment losses.

i. **Goods and Services Tax (GST)**

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of expense. Receivables and payables in the Statement of Financial Position are shown inclusive of GST.

The net amount of GST recoverable from, or payable to, the taxation authority is included as a current asset or liability in the statement of financial position.

Cash flows are presented in the Cash Flow Statement on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

j. **Provisions**

Provisions are recognised when the company has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. Provisions recognised represent the best estimate of the amounts required to settle the obligation at the end of the reporting period.

k. **Trade and Other Payables**

Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the company during the reporting period which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

l. **Comparative Figures**

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

m. **Critical Accounting Estimates and Judgments**

The directors evaluate estimates and judgments incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company.

Key estimates — Impairment

The company assesses impairment at each reporting date by evaluating conditions specific to the company that may lead to impairment of assets. Where an impairment trigger exists, the recoverable amount of the asset is determined. Value-in-use calculations performed in assessing recoverable amounts incorporate a number of key estimates.

n. **New Accounting Standards for Application in Future Periods**

The AASB has issued other new and amended Accounting Standards and Interpretations that have mandatory application dates for future reporting periods and which the company has decided not to early adopt. These standards detail numerous non-urgent but necessary changes to Accounting Standards arising from the IASB's annual improvements project. No changes are expected to materially affect the company.

These notes form part of the financial statements

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 2: REVENUE	2012	2011
	\$	\$
Operating activities:		
- legacies & bequests	-	-
- operating grants - Australian	3,727,824	3,466,521
- other grants – Ausaid	381,836	669,832
- other grants – overseas	229,577	53,971
	<hr/>	<hr/>
3	4,339,237	4,190,324
- donations	81,614	26,210
- member subscriptions	83,003	37,360
- sponsorship	124,909	116,591
- conference	5,171,510	4,836,914
- other revenue from operating activities	969,855	1,084,675
- interest received	109,739	111,509
- Support to the sector	136,849	-
	<hr/>	<hr/>
	11,016,715	10,403,583

NOTE 3: EXCESS OF REVENUE OVER EXPENDITURE BEFORE INCOME TAX EXPENSE

Excess of revenue over expenditure before income tax expense has been determined after charging the following items:

Revenue: *Operating Grants*

Grants - AusAid

- HIV Consortium Capacity Development	300,432	391,785
- HIV and Viral Hepatitis Co-Infection Management in Asia	37,065	112,426
- Study Tour: Comprehensive Drug Treatment & Diversion Program in Australia	-	165,621
- International short course HIV medicine/related issues	19,675	-
- Support for Vietnamese Deputy Prime Minister Visit	24,664	-

Grants Commonwealth

- Hepatitis – Annual program of activities	488,100	390,510
- HIV / AIDS and STI Education program	508,900	589,650
- The Aboriginal and Torres Strait Islander BBV and STI project	272,727	302,418

Grants NSW Health

- Viral Hepatitis program	733,884	655,744
- Population Health Services (AIDS) and Sexual Health Nursing Training	582,476	517,387
- Workforce Development program	371,085	358,727
- Aboriginal Clinical Care	65,468	102,019
- Public Health Liaison and Surveillance	121,900	110,333
- Indigenous Early Childhood Development	-	90,000
- STI/HIV/Hepatitis C workforce	40,000	-
- HARPM Workforce Development	26,000	-

Grants – WA Workforce development and training

Grants other – overseas projects	433,224	331,551
Grants other – domestic projects	34,800	18,182
Grants - overseas	229,577	53,971

	4,339,237	4,190,324
--	-----------	-----------

These notes form part of the financial statements

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 3: EXCESS OF REVENUE OVER EXPENDITURE BEFORE INCOME TAX EXPENSE (cont.)

	2012	2011
	\$	\$
Expenses:		
Depreciation expenses	85,274	92,541
Impairment expenses	-	12,030
Rental expense on operating leases		
— rental expense	192,727	185,539
Remuneration of auditor		
— audit or review	28,949	23,120
— other services	-	-
	28,949	23,120

NOTE 4: KEY MANAGEMENT PERSONNEL COMPENSATION

Any person(s) having authority and responsibility for planning, directing and controlling the activities of the company, directly or indirectly, including any director (whether executive or otherwise) is considered key management personnel.

Key Management Person	Short-term Benefits				Post-employment Benefits
	Salary	Bonuses	Non-cash benefit	Other	Super-annuation
2012	\$	\$	\$	\$	\$
Key management personnel compensation	220,168	-	-	18,650	23,791
2011					
Key management personnel compensation	147,421	-	-	27,684	17,510

NOTE 5: CASH AND CASH EQUIVALENTS

	Note	2012	2011
		\$	\$
Cash on hand		630	630
Cash at bank		428,626	351,369
Short-term bank deposits		2,888,395	2,877,372
	18	3,317,651	3,229,371

The effective interest rate on short-term bank deposits was 3.50%; these deposits are at call.

NOTE 6: TRADE AND OTHER RECEIVABLES

CURRENT

Trade and other receivables		900,330	549,040
Work in progress – conferences		364,746	303,645
Total current receivables	18	1,265,076	852,685

(i) Provision for Impairment of Receivables

Current trade receivables are non-interest bearing loans and are generally receivable within 60 days. These receivables are assessed for recoverability and a provision for impairment is recognised where there is objective evidence that an individual trade receivable is impaired. No impairment was required at 30 June 2012.

These notes form part of the financial statements

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 6: TRADE AND OTHER RECEIVABLES (CONT.)

(ii) Credit Risk — Receivables

The company does not have any material credit risk exposure to any single receivable or group of receivables.

The following table details the company's receivables exposed to credit risk (prior to collateral and other credit enhancements) with ageing analysis and impairment provided for thereon. Amounts are considered as 'past due' when the debt has not been settled within the terms and conditions agreed between the company and the customer or counter party to the transaction. Receivables that are past due are assessed for impairment by ascertaining solvency of the debtors and are provided for where there are specific circumstances indicating that the debt may not be fully repaid to the company.

The balances of receivables that remain within initial trade terms (as detailed in the table) are considered to be of high credit quality.

	Gross amount	Past due and impaired	Past due but not impaired (days overdue)				Within initial trade terms
	\$	\$	< 30	31–60	61–90	> 90	\$
2012							
Trade receivables	895,036	-	742,801	77,676	5,000	69,559	895,036
Total	895,036	-	742,801	77,676	5,000	69,559	895,036
2011							
Trade receivables	542,134	-	365,097	166,104	4,400	6,533	542,134
Total	542,134	-	365,097	166,104	4,400	6,533	542,134

The company does not hold any financial assets whose terms have been renegotiated, but which would otherwise be past due or impaired.

There are no balances within receivables that contain assets that are not impaired and are past due. It is expected that these balances will be received when due.

	Note	2012 \$	2011 \$
NOTE 7: OTHER ASSETS			
CURRENT			
Prepayments		6,975	19,735
		<u>6,975</u>	<u>19,735</u>

NOTE 8: OTHER FINANCIAL ASSETS

CURRENT			
Held to maturity investments		400,000	400,000
NON-CURRENT			
Held to maturity investments		58,489	58,489

Held-to-maturity investments comprise:

— Current: Term deposit		400,000	400,000
— Non-Current: Term deposit		58,489	58,489
	18	<u>458,489</u>	<u>458,489</u>

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

	2012 \$	2011 \$
NOTE 9: PROPERTY, PLANT AND EQUIPMENT		
Office Equipment:		
At cost	21,024	21,024
Accumulated depreciation	(14,662)	(13,072)
	6,362	7,952
Leasehold improvements:		
At cost	244,474	240,311
Accumulated depreciation	(112,131)	(95,065)
Impairment loss	(12,031)	(12,030)
	120,312	133,216
Computer Equipment:		
At cost	248,547	279,609
Accumulated depreciation	(174,803)	(196,249)
	73,744	83,360
Furniture, fixtures and fittings:		
At cost	85,864	85,864
Accumulated depreciation	(57,068)	(53,132)
	28,796	32,732
Software pool:		
At cost	153,915	153,915
Accumulated depreciation	(120,468)	(100,462)
	33,447	53,453
Motor Vehicles		
At cost	35,222	35,222
Accumulated depreciation	(18,641)	(14,815)
	16,581	20,407
	279,242	331,120

	Lease. Imp.	Motor Vehicles	Office Equip.	Computer Equip.	Furn., Fixt. & Fittings	Software	Total
	\$	\$	\$	\$	\$	\$	\$

Movements in Carrying Amounts

Movement in the carrying amounts for each class of property, plant and equipment between the beginning and the end of the current financial year.

Balance at 30 June 2011	133,216	20,407	7,952	83,360	32,732	53,453	331,120
Additions	4,163	-	-	29,558	-	-	33,721
Disposals	-	-	-	(325)	-	-	(325)
Depreciation expense	(17,067)	(3,826)	(1,590)	(38,849)	(3,936)	(20,006)	(85,274)
Impairment expense	-	-	-	-	-	-	-
Carrying amount at 30 June 2012	120,312	16,581	6,362	73,744	28,796	33,447	279,242

These notes form part of the financial statements

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

		2012 \$	2011 \$
NOTE 10: TRADE AND OTHER PAYABLES	Note		
Trade payables		271,060	382,775
Income in advance		1,547,201	1,211,423
Sundry creditors		360,269	317,852
	10a	<u>2,178,530</u>	<u>1,912,050</u>

a. **Financial liabilities at amortised cost classified as trade and other payables**

CURRENT

Trade and other payables

— Total current	2,178,530	1,912,050
— Total non-current	-	-

2,178,530 1,912,050

Financial liabilities as trade and other payables	18	<u>2,178,530</u>	<u>1,912,050</u>
---	----	------------------	------------------

NOTE 11: CURRENT PROVISIONS

CURRENT

Annual Leave and Long Service Leave	301,409	202,298
-------------------------------------	---------	---------

NOTE 12: EMPLOYEE BENEFITS

	Long-term Employee Benefits \$	Total \$
Opening balance at 30 June 2011	113,464	113,464
Additional provisions raised during period	55,441	55,441
Amounts used	(27,720)	(27,720)
Balance at 30 June 2012	<u>141,185</u>	<u>141,185</u>

Analysis of Total Provisions

	2012 \$	2011 \$
Current – Annual leave	264,788	202,298
Current – Long service leave	36,621	-
	<u>301,409</u>	<u>202,298</u>
Non-Current	<u>104,564</u>	<u>113,464</u>
	<u>405,973</u>	<u>315,672</u>

Provision for Long-term employee entitlements

A provision has been recognised for employee entitlements relating to long service leave. In calculating the present value of future cash flows in respect of long service leave, the probability of long service leave being taken is based on historical data. The measurement and recognition criteria relating to employee entitlements have been included in Note 1 to this report.

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

	2012 \$	2011 \$
NOTE 13: CAPITAL AND LEASING COMMITMENTS		
Operating Lease Commitments		
Non-cancellable operating leases contracted for but not capitalised in the financial statements:		
Payable — minimum lease payments		
— not later than 12 months	204,631	198,679
— between 12 months and 5 years	200,167	405,979
— greater than 5 years	-	-
	<u>404,798</u>	<u>604,658</u>
NOTE 14: CASH FLOW INFORMATION		
a. Reconciliation of Cash		
Cash at the end of the financial year as shown in the statements of cash flows is reconciled to the related items in the statement of financial position as follows:		
Cash on hand	630	630
Cash at bank	428,626	351,369
Short-term bank deposits	2,888,395	2,877,372
	<u>3,317,651</u>	<u>3,229,371</u>
b. Reconciliation of cash flow from operations with profit from ordinary activities after income tax		
Profit from ordinary activities after income tax expense	79,342	27,381
<i>Non-cash flows in profit from ordinary activities</i>		
Loss on disposal of plant and equipment	325	1,059
Depreciation and impairment	85,274	104,571
<i>Changes in assets and liabilities</i>		
Decrease / (Increase) in receivables	(412,391)	1,170,360
Decrease / (Increase) in prepayments	12,760	2,358
Increase / (Decrease) in payables	266,480	(1,351,215)
Increase in provision	90,211	53,271
Net cash provided by operating activities	<u>122,001</u>	<u>7,785</u>

These notes form part of the financial statements

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 15: CONTINGENT LIABILITIES

To the Directors' knowledge, the company has no known contingent liabilities as at 30 June 2012.

NOTE 16: SEGMENT REPORTING

The company operates predominantly in one business and geographical segment, being a professional body for medical practitioners and health care professionals who work in HIV, viral hepatitis and related diseases, in Australia.

NOTE 17: EVENTS SUBSEQUENT TO BALANCE DATE

There have been no significant events after 30 June 2012 to date of signing report.

NOTE 18: FINANCIAL INSTRUMENTS

The company's financial instruments consist mainly of deposits with banks, local money market instruments, short-term investments, accounts receivable and payable and leases.

The totals for each category of financial instruments, measured in accordance with AASB 139 as detailed in the accounting policies to these financial statements, are as follows:

	Note	2012 \$	2011 \$
Financial Assets			
Cash and cash equivalents	5	3,317,651	3,229,371
Loans and receivables	6	1,265,076	852,685
Held-to-maturity investments:			
– Term Deposits	8	458,489	458,489
Total Financial Assets		5,041,216	4,540,545
Financial Liabilities			
Financial liabilities at amortised cost			
– Payables	10a	2,178,530	1,912,050
Total Financial Liabilities		2,178,530	1,912,050

Specific Financial Risk Exposures and Management

The main risks the company is exposed to through its financial instruments are credit risk, liquidity risk and market risk relating to interest rate risk. There have been no substantive changes in the types of risks the company is exposed to, how these risks arise, or the board's objectives, policies and processes for managing or measuring the risk from the previous period

a. Credit Risk

Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss for the company.

Credit Risk Exposures

The maximum exposure to credit risk by class of recognised financial assets at the end of the reporting period is equivalent to the carrying value and classification of those financial assets (net of any provisions) as presented in the statement of financial position.

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 18: FINANCIAL INSTRUMENTS (CONT.)

a. Credit Risk (cont.)

The company does not have any material credit risk exposure to any single receivable or group of receivables under financial instruments entered into by the company.

Trade and other receivables that are neither past due or impaired are considered to be of high credit quality. Aggregates of such amounts are as detailed at Note 6.

The company has no significant concentration of credit risk exposure to any single counterparty or group of counterparties. Details with respect to credit risk of Trade and Other Receivables are provided in Note 6.

b. Liquidity risk

Liquidity risk arises from the possibility that the company might encounter difficulty in settling its debts or otherwise meeting its obligations in relation to financial liabilities. The company manages this risk through the following mechanisms:

By monitoring forecast cash flows in relation to its operational, investing and financing activities, and ensuring that adequate un-utilised borrowing facilities are maintained.

The tables below reflect an undiscounted contractual maturity analysis for financial liabilities.

Cash flows realised from financial assets reflect management's expectation as to the timing of realisation. Actual timing may therefore differ from that disclosed. The timing of cash flows presented in the table to settle financial liabilities reflects the earliest contractual settlement dates.

Financial liability and financial asset maturity analysis

	Within 1 Year		1 to 5 Years		Over 5 Years		Total	
	2012	2011	2012	2011	2012	2011	2012	2011
	\$	\$	\$	\$	\$	\$	\$	\$
Financial liabilities due for payment								
Payables (excluding estimated annual leave and income in advance)	631,329	700,627	-	-	-	-	631,329	700,627
Total expected outflows	631,329	700,627	-	-	-	-	631,329	700,627

Financial liability and financial asset maturity analysis

	Within 1 Year		1 to 5 Years		Over 5 Years		Total	
	2012	2011	2012	2011	2012	2011	2012	2011
	\$	\$	\$	\$	\$	\$	\$	\$
Financial Assets — cash flows realisable								
Cash and cash equivalents	3,317,651	3,229,371	-	-	-	-	3,317,651	3,229,371
Trade and other receivables (exclude work in progress)	900,330	549,040	-	-	-	-	900,330	549,040
Held-to-maturity investments	400,000	400,000	58,489	58,489	-	-	458,489	458,489
Total anticipated inflows	4,617,981	4,178,411	58,489	58,489	-	-	4,676,470	4,236,900
Net inflow on financial instruments	3,986,652	3,477,784	58,489	58,489	-	-	4,045,141	3,536,273

These notes form part of the financial statements

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 18: FINANCIAL INSTRUMENTS (CONT.)

c. Market Risk

i. Interest rate risk

Exposure to interest rate risk arises on financial assets and financial liabilities recognised at the end of the reporting period whereby a future change in interest rates will affect future cash flows or the fair value of fixed rate financial instruments.

The company is not exposed to any significant interest rate risk since cash balances are maintained at variable rates and the company has no borrowings.

ii. Price risk

Price risk relates to the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices of securities held.

The company is not exposed to any material commodity price risk.

Sensitivity analysis:

The following table illustrates sensitivities to the company's exposures to changes in interest rates and equity prices. The table indicates the impact on how profit and equity values reported at the end of the reporting period would have been affected by changes in the relevant risk variable that management considers to be reasonably possible. These sensitivities assume that the movement in a particular variable is independent of other variables.

	Profit	Equity
	\$	\$
Year ended 30 June 2012		
— +/-1% in interest rates	33,177	33,177
Year ended 30 June 2011		
— +/-1% in interest rates	32,294	32,294

No sensitivity analysis has been performed on foreign exchange risk as the company is not exposed to foreign currency fluctuations.

d. Net fair values

The fair values of financial assets and financial liabilities are presented in the following table and can be compared to their carrying values as presented in the statement of financial position. Fair values are those amounts at which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arm's length transaction.

Differences between fair values and carrying values of financial instruments with fixed interest rates are due to the change in discount rates being applied by the market since their initial recognition by the company. Most of these instruments which are carried at amortised cost (i.e. trade receivables, loan liabilities) are to be held until maturity and therefore the net fair value figures calculated bear little relevance to the company.

These notes form part of the financial statements

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 18: FINANCIAL INSTRUMENTS (CONT.)

		30 June 2012		30 June 2011	
	Note	Net Carrying Value	Net Fair Value	Net Carrying Value	Net Fair Value
		\$	\$	\$	\$
Financial assets					
Cash and cash equivalents	(i)	3,317,651	3,317,651	3,229,371	3,229,371
Trade and other receivables	(i)	900,370	900,370	549,040	549,040
		4,218,021	4,218,021	3,778,411	3,778,411
<i>Held-to-maturity financial assets:</i>					
– Government and fixed interest securities	(ii)	458,489	458,489	458,489	458,489
Total financial assets		4,676,510	4,676,510	4,236,900	4,236,900
Financial liabilities					
Payables	(i)	631,329	631,329	700,627	700,627
Total financial liabilities		631,329	631,329	700,627	700,627

The fair values disclosed in the above table have been determined based on the following methodologies:

- (i) Cash and cash equivalents, receivables and payables are short-term instruments in nature whose carrying value is equivalent to fair value. Receivables exclude work in progress, and payables exclude amounts provided for annual leave and income in advance, as these are not considered a financial instrument.
- (ii) Fair values of held-to-maturity investments are based on quoted market prices at the end of the reporting period.

Financial Instruments Measured at Fair Value

The financial instruments recognised at fair value in the Statement of Financial Position have been analysed and classified using a fair value hierarchy reflecting the significance of the inputs used in making the measurements between those for which fair value is based on. The fair value hierarchy consists of the following levels:

Financial Instruments Measured at Fair Value

30 June 2012	Level 1	Level 2	Level 3	Total
	\$	\$	\$	\$
Financial assets:				
Held-to-maturity financial assets	458,489	-	-	458,489
	458,489	-	-	458,589
30 June 2011	Level 1	Level 2	Level 3	Total
	\$	\$	\$	\$
Financial assets:				
Held-to-maturity financial assets	458,489	-	-	458,489
	458,489	-	-	458,489

Included within Level 1 of the hierarchy are listed investments. The fair values of these financial assets have been based on the closing quoted bid prices at the end of the reporting period, excluding transaction costs.

These notes form part of the financial statements

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2012

NOTE 19: CAPITAL MANAGEMENT

Management controls the capital of the company to ensure that adequate cash flows are generated to fund the ongoing operations of the company. The Board ensures that the overall risk management strategy is in line with this objective.

Risk management strategies are approved and reviewed by the Board on a regular basis. These include future cash flow requirements.

The company's capital consists of financial liabilities, supported by financial assets.

Management effectively manages the company's capital by assessing the company's financial risks and responding to changes in these risks and in the market. These responses may include the consideration of debt levels and the maintenance of an appropriate debt facility.

NOTE 20: COMPANY DETAILS

The registered office and principal place of business of the company is:

Australasian Society For HIV Medicine
Level 7, 46-56 Kippax St.
SURRY HILLS NSW 2010

NOTE 21: MEMBERS GUARANTEE

The company is incorporated under the Corporations Act 2001 and is a company limited by guarantee. If the company is wound up the constitution states that each member is required to contribute \$1 towards meeting any outstanding obligations of the company. At 30 June 2012 the number of members was 1,181 (2011: 1,145.)

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

DIRECTORS' DECLARATION

The Directors of the Company declare that:

1. The financial statements and notes, as set out on pages 10 to 27 are in accordance with the Corporations Act 2001:
 - a. comply with Australian Accounting Standards and the Corporations Regulations 2001; and
 - b. give a true and fair view of the Company's financial position as at 30 June 2012 and of the performance for the year ended on that date.
2. In the Directors' opinion there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.



Prof Gregory Dore BSc MBBS FRACP MPH PhD



Dr Mark Boyd BA BM BS MHID MD FRACP

Dated this 19th day of September 2012

INDEPENDENT AUDIT REPORT TO THE MEMBERS OF AUSTRALASIAN SOCIETY FOR HIV MEDICINE

Report on the Financial Report

We have audited the accompanying financial report of Australasian Society For HIV Medicine, which comprises the statement of financial position as at 30 June 2012, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Directors' Responsibility for the Financial Report

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards (including the Australian Accounting Interpretations) and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error. The directors have also prepared the financial report so that it incorporates elements of the Australian Council for International Development (ACFID) Code of Conduct.

Audit Responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of the financial report that gives a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Independence

In conducting our audit, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of Australasian Society For HIV Medicine on 30 June 2012, would be in the same terms if given to the directors as at the time of this auditor's report.

ABN 55 931 152 366

8th Floor,
55 Hunter Street
SYDNEY NSW 2000

GPO Box 4836
SYDNEY NSW 2001

Telephone: +61 2 9951 5400
Facsimile: +61 2 9951 5454
mail@wwnsw.com.au

Website www.wwnsw.com.au

**INDEPENDENT AUDIT REPORT TO THE MEMBERS OF
AUSTRALASIAN SOCIETY FOR HIV MEDICINE**

Audit Opinion

In our opinion, the financial report of Australasian Society For HIV Medicine is in accordance with the Corporations Act 2001, including:

- a. giving a true and fair view of the Company's financial position as at 30 June 2012 and of the performance for the year ended on that date ; and
- b. complying with Accounting Standards (including the Australian Accounting Interpretations) and the Corporations Regulations 2001

Walker Wayland nsw A S Roger

Walker Wayland NSW
Chartered Accountants

A S Roger
Partner

Dated this 19th day of September 2012

**COMPILATION REPORT ON ADDITIONAL FINANCIAL DATA
TO THE MEMBERS OF AUSTRALASIAN SOCIETY FOR HIV MEDICINE**

Telephone: +61 2 9951 5400
Facsimile: +61 2 9951 5454
mail@wwnsw.com.au

Website www.wwnsw.com.au

Scope

We have compiled the accompanying Statement of Comprehensive Income of Australasian Society for HIV Medicine for the year ended 30 June 2012 on the basis of information provided by the directors. The specific purpose for which the Statement of Comprehensive Income, prepared in accordance with the ACFID Code of Conduct, has been prepared to provide detailed information relating to the performance of the entity that satisfies the information needs of directors and members.

The Responsibility of the Directors of Australasian Society for HIV Medicine

The directors of the Company are solely responsible for the information contained in the Statement of Comprehensive Income, and determined that the basis of accounting adopted is appropriate to meet their needs and for the purpose that the financial statements were prepared.

Our Responsibility

On the basis of information provided by the directors of the Company, we have compiled the accompanying statement in accordance with the basis of accounting adopted and APES 315: Compilation of Financial Information.

Our procedures use accounting expertise to collect, classify and summarise the financial information, which the directors provided, in compiling the financial statement. Our procedures do not include verification or validation procedures. No audit or review has been performed and accordingly no assurance is expressed.

The Statement of Comprehensive Income was compiled exclusively for the benefit of the directors of Australasian Society for HIV Medicine. We do not accept responsibility to any other person for the contents of the Statement of Comprehensive Income Statement.

Walker Wayland n s w

A S Roger

Walker Wayland NSW
Chartered Accountants

A S Roger
Partner

Dated this 19th day of September 2012

AUSTRALASIAN SOCIETY FOR HIV MEDICINE

A.C.N 139 281 173

A COMPANY LIMITED BY GUARANTEE

STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2012

	2012 \$	2011 \$
REVENUE		
Donations and gifts		
- Monetary	81,614	26,210
- Non-monetary	-	-
Bequests and legacies	-	-
Grants		
- AusAid	381,836	669,832
- Other Australian	3,727,824	3,466,521
- Other overseas	229,577	53,971
Investment income	109,739	111,509
Other income	6,486,125	6,075,540
TOTAL REVENUE	11,016,715	10,403,583
EXPENDITURE		
International Aid and Development Program Expenditure		
International programs		
- Funds to international programs	44,354	79,792
- Program support costs	694,380	937,896
Community education	-	-
Fundraising costs		
- Public	1,488	2,928
- Government, multilateral and private	11,886	-
Accountability and administration	115,614	130,599
Non-monetary expenditure	-	-
Total International Aid and Development Programs Expenditure	867,722	1,151,215
Domestic programs expenditure	10,069,651	9,224,987
TOTAL EXPENDITURE	10,937,373	10,376,202
EXCESS/(SHORTFALL) OF REVENUE OVER EXPENDITURE	79,342	27,381
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	79,342	27,381

During the financial year, ASHM had no transactions in the Political or Religious Adherence Promotion Programs category.

Fundraising costs – government, multilateral and private relate to fundraising via grant preparation (not charitable, benevolent, philanthropic donations).

No single appeal, grant or other form of fund raising for a designated purpose generated 10% or more of the ASHM international aid and development revenue for the financial year.

This statement should be read in conjunction with the attached compilation report